Recombinant Human TNFSF14, FLAG-tagged
Cat.No. : | TNFSF14-392H |
Product Overview : | Human LIGHT (aa 89-240) is fused at the N-terminus to a FLAG-tag. |
- Specification
- Gene Information
- Related Products
- Download
Description : | LIGHT (HVEML; CD258) is a cytokine that binds to TNFRSF3/LTBR. It activates NF-kappa;B, stimulates the proliferation of T cells, and inhibits growth of the adenocarcinoma HT-29. Acts as a receptor for Herpes simplex virus. |
Source : | CHO Cells |
Species : | Human |
Tag : | FLAG |
Form : | Lyophilized. Contains PBS. |
Molecular Mass : | ~25kDa (SDS-PAGE) |
Purity : | ≥95% (SDS-PAGE) |
Stability : | Stable for at least 6 months after receipt when stored at -20°C. |
Storage : | Short Term Storage: +4°C; Long Term Storage: -20°C. After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. PBS containing at least 0.1% BSA should be used for further dilutions. |
Concentration : | 0.1mg/ml after reconstitution. |
Protein length : | 89-240 |
Gene Name : | TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ] |
Official Symbol : | TNFSF14 |
Synonyms : | TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML; |
Gene ID : | 8740 |
mRNA Refseq : | NM_003807 |
Protein Refseq : | NP_003798 |
MIM : | 604520 |
UniProt ID : | O43557 |
Chromosome Location : | 19p13.3 |
Pathway : | Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Herpes simplex infection, organism-specific biosystem; Herpes simplex infection, conserved biosystem; |
Function : | cysteine-type endopeptidase inhibitor activity involved in apoptotic process; cytokine activity; protein binding; receptor binding; tumor necrosis factor receptor binding; |
Products Types
◆ Recombinant Protein | ||
TNFSF14-303H | Active Recombinant Human TNFSF14 Protein (Arg64-Val240), C-His tagged, Animal-free, Carrier-free | +Inquiry |
TNFSF14-4501H | Recombinant Human TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
TNFSF14-288H | Recombinant Human TNFSF14 Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
TNFSF14-9484M | Recombinant Mouse TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
TNFSF14-783C | Recombinant Cynomolgus Monkey TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket